CIAM
ALLO icon

Caitong International Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Caitong International Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$173K Buy
70,933
+26,599
+60% +$53.3K 0.03% 424
2025
Q4 		$60.7K Buy
44,334
+20,287
+84% +$26.8K 0.01% 629
2025
Q3 		$29.8K Buy
24,047
+23,599
+5,268% +$28.1K 0.02% 498
2025
Q2 		$506 Sell
448
-176
-28% -$234 ﹤0.01% 1695
2025
Q1 		$911 Buy
624
+474
+316% +$894 ﹤0.01% 1595
2024
Q4 		$320 Buy
+150
New +$370 ﹤0.01% 1530

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caitong International Asset Management's ALLO Position: Q1 2026 in Review

Caitong International Asset Management increased its Allogene Therapeutics (ALLO) stake by 60% in Q1 2026, buying an estimated $53.3K and bringing the position to 70,933 shares worth $173K. The position accounts for 0.03% of the portfolio, ranked #424.

Caitong International Asset Management first reported a position in ALLO in Q4 2024 and has held it in 6 quarters since. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Caitong International Asset Management held 70,933 shares of Allogene Therapeutics worth $173K as of Q1 2026.
  • Caitong International Asset Management bought 26,599 Allogene Therapeutics shares in Q1 2026, an estimated $53.3K.
  • Allogene Therapeutics made up 0.03% of Caitong International Asset Management's portfolio in Q1 2026, its #424 holding.
  • Caitong International Asset Management first reported a position in Allogene Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.